The recent study conducted by researchers from Stanford University has shed light on the dysfunctions in two specific brain systems in individuals experiencing psychosis. These systems play a crucial role in filtering attention to important internal and external information, as well as predicting or anticipating rewards. Understanding these dysfunctions is essential in developing effective treatments
0 Comments
A groundbreaking treatment candidate for amyotrophic lateral sclerosis (ALS) has shown promising results in the phase IIb PARADIGM trial. Developed as a formulation of two FDA-approved drugs, ciprofloxacin and celecoxib, PrimeC demonstrated positive safety outcomes for ALS patients, with similar results to those treated with a placebo. Massachusetts General Hospital’s Merit Cudkowicz, MD, MSc, presented
0 Comments